Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy.
Saranda NianpanichRatchanee RodsiriRidho IslamiePatanachai LimpikiratiThanundorn ThanusuwannasakOpa VajraguptaApinan KanasuwanJiradanai SarasamkanPublished in: Psychopharmacology (2024)
These findings suggest that (S)-T1 and (S)-T2 hold promise for treating nicotine addiction by attenuating nicotine-induced CPP and modulating dopamine release in key reward-related brain regions. Further research is needed to gain insights into the underlying mechanisms behind their anti-addictive effects and substantiate their potential for treating nicotine addiction.